Brian McCartney

Brian has responsibility to proactively monitor drug pricing reform issues – including legislative, regulatory and administrative actions at the federal and state level – that could impact strategic and business outcomes for McKesson and our customers, partners and other industry stakeholders in the U.S. pharmaceutical value chain. Brian assess’ financial implications for McKesson, and develops strategies and operational solutions to manage risk and drive business value, harnessing the breadth and depth of enterprise assets and capabilities.

Brian comes to McKesson with over 17 years of pharmaceutical manufacturer experience in government pricing and policy at J&J, Endo Pharmaceuticals and most recently at AstraZeneca. During his tenure at AstraZeneca, Brian helped the company navigate drug pricing reform by strategically partnering with Policy, Finance, Account Teams and Contract Strategy to mitigate the impacts of the Inflation Reduction Act, AMP Cap Removal etc. Brian is a subject matter expert in government price reporting that gives him a deep understanding of the U.S. pharmaceutical supply chain, including 340B, buy and bill and diverse payer segments.